



[Print](#) | [Close this window](#)

ImmunoCellular in research and license option deal with Roche

Wed Sep 9, 2009 8:16am EDT

Sept 9 (Reuters) - ImmunoCellular Therapeutics Ltd (IMUC.OB: [Quote](#), [Profile](#), [Research](#), [Stock Buzz](#)) signed a research and license option deal with Roche Holding AG (ROG.VX: [Quote](#), [Profile](#), [Research](#), [Stock Buzz](#)), granting Roche rights to investigate the potential of its ICT-69 antibody in the diagnosis and treatment of multiple myeloma and ovarian cancer.

ImmunoCellular will get an unspecified upfront payment and upon completion of the evaluation period, Roche has the right to acquire a commercial licence for ICT-69 for an option exercise payment, the biotechnology company said in a statement.

ImmunoCellular said it could receive up to \$32 million in total payments from Roche if all developmental milestones are met.

Royalties will also be payable to ImmunoCellular based on Roche's worldwide sales of ICT-69 products, the statement said.

(Reporting by Shailesh Kuber in Bangalore; Editing by Aradhana Aravindan)

© Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.